Bionano Genomics, Inc. Cash Flow Statement
BNGO|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$16M
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Bionano Genomics, Inc. used $16M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -8.45 (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -59.4% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$26.4M | -$112.0M | -$232.5M | -$132.6M | -$72.4M | -$41.1M | -$29.8M | -$18.5M |
| Depreciation & Amortization | $9.5M | $14.0M | $13.7M | $9.6M | $3.4M | $1.5M | $1.1M | $1.3M |
| Operating Cash Flow | -$16.3M | -$68.9M | -$125.2M | -$124.8M | -$71.9M | -$38.3M | -$29.5M | -$19.9M |
| Capital Expenditures | - | - | - | - | - | $0 | $61.1K | $331.7K |
| Free Cash Flow | - | - | - | - | - | -$38.3M | -$29.6M | -$20.3M |
| FCF Margin | - | - | - | - | - | -450.6% | -292.1% | -168.9% |